Boston Therapeutics, Inc. (BTHE)

Take a look at some of our previously featured companies

Boston Therapeutics, Inc. (BTHE)

Postby QualityStocks » Fri Oct 04, 2013 4:02 pm

Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company's position in the pharmaceutical industry. Boston Therapeutics' current product pipeline, PAZ320 and IPOXYNT, is comprised of therapies developed to treat patient populations with Type 2 diabetes.

PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics believes PAZ320 is a safe and effective drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels, fulfilling an unmet medical need. PAZ320 has completed a Phase ll clinical trial at Dartmouth Medical Center. 45% of the patients responded with a 40% reduction in the elevation of post meal blood sugar compared to baseline with no serious adverse events.

IPOXYNT, a universal oxygen carrier, is an injectable Rx for prevention of necrosis and treatment of ischemic conditions which may lead to necrosis. This compound is not a biologic, but a second generation New Chemical Entity HBOC (hemoglobin based oxygen carrier). The potential for this product goes well beyond Lower Limb Ischemia into a range of areas from anemia and blood loss (injury), to cardiovascular disease and surgical blood supplementation.

The Boston Therapeutics management and advisory team has extensive expertise in complex carbohydrate chemistry, regulatory affairs, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration. Backed by a team with more than five decades of expertise in public and private business management, the company is well positioned to advance its status as a premier developer of complex carbohydrate-based new chemical entities.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 433
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Boston Therapeutics, Inc. (BTHE)

Postby ssh5558 » Fri Oct 04, 2013 7:36 pm

Such an important product because millions of humans suffer from Type 2 Diabetes and do nothing to control it.
I am not an official or registered investment advisor, but do receive payment from DreamTeamGroup for research services (full disclaimer: http://dreamteamgroup.com/disclaimer.html).
ssh5558
 
Posts: 0
Joined: Wed Aug 14, 2013 4:05 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Fri Oct 04, 2013 7:45 pm

BTHE is looking to find success as this drug is; non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Mon Oct 07, 2013 6:33 am

An easy-to-use way of addressing one of the most important health markets in the country. Hard to ask for more.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Mon Oct 07, 2013 9:40 pm

Especially when Diabetes is so prevalent unfortunately
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Tue Oct 08, 2013 5:13 am

Anyway, share price has exploded.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Tue Oct 08, 2013 2:49 pm

Their drug PAZ320 also ensures help for pre-diabetes as well
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Wed Oct 09, 2013 6:06 am

And IPOXYNT, although not as simple to use as PAZ320 , can basically stop cells from dying, with many medical applications.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Wed Oct 09, 2013 7:13 pm

Truly amazing when you consider it all imagine a way to prevent cells from dying
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Thu Oct 10, 2013 5:38 am

That's why the potential for IPOXYNT goes beyond just lower limb ischemia, and into things like anemia and blood loss and even heart disease.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Thu Oct 10, 2013 6:24 pm

Hoping to solve some very life threatening problems for sure
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Fri Oct 11, 2013 5:35 am

Cell death is key to many diseases.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Boston Therapeutics, Inc. (BTHE)

Postby QualityStocks » Fri Oct 11, 2013 2:52 pm

Article Highlights Major Investment Points for Boston Therapeutics, Inc. (BTHE)

A recent BiotechStockTrader.com article (http://dtg.fm/SyR6), highlighting the unique and positive position that Boston Therapeutics now holds with regard to the multi-billion dollar diabetes drug industry, laid out the reasons why investors are starting to jump on board the still small biotech company.

The company’s lead drug candidate, PAZ320, is the first diabetes drug to be based upon an important new technology, carbohydrate hydrolyzing enzyme inhibiting (CHEI). Unlike traditional diabetes drugs, PAZ320 doesn’t require insulin injections, and doesn’t involve interaction with important internal organs, such as the pancreas, kidneys, or liver. Instead, it is a simple chewable that operates in the gastrointestinal track, and has already been shown to be dramatically effective at stopping sugar before it even gets into the blood stream.

The article pointed out a number of reasons that Boston Therapeutics could be the next hot drug stock:

• Diabetes drugs are huge money makers, with the top 10 diabetes drugs generating well over $1 billion in annual sales, in some cases over $6 billion.

• The overall diabetes drug market is expected to grow to $58 billion by 2018.

• The number of people with diabetes has exploded over the past 10 years, and is expected to climb to over ½ billion by 2030.

• Type 2 diabetes, that targeted by Boston Therapeutics, represents approximately 95% of all diabetes cases.

• Being the first CHEI diabetes drug, Boston Therapeutics’ PAZ320 is clearly differentiated.

• In a Phase II clinical trial of PAZ320 at Dartmouth, 45% of the Type 2 diabetes patients showed a whopping 40% reduction in post-meal glucose.

• PAZ320 is easier to administer, being a simple chewable, and could avoid serious side effects sometimes found in standard drugs that that must interact with vital organs.

• PAZ320 has been shown to be effective regardless of other medications being used by the patient.

For additional information, visit www.BostonTI.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 433
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Fri Oct 11, 2013 10:06 pm

Not having to rely heavily on insulin shots is huge to consider
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Mon Oct 14, 2013 5:34 am

There are a lot of diabetes drugs, but the top ones earn over a billion dollars a year in revenue, with the best earning over $6 billion.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Mon Oct 14, 2013 8:59 pm

The results the drug has on it's patient is so very important
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Tue Oct 15, 2013 5:42 am

If you're talking about PAZ320, it's indeed revolutionary, a first-in-class drug to limit sugar uptake, and it's chewable.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Re: Boston Therapeutics, Inc. (BTHE)

Postby stockseeker30 » Tue Oct 15, 2013 6:19 pm

Wow what a huge push upwards today
I am not a registered investment adviser. Do your own due diligence and keep in mind I receive payment from DreamTeamGroup for research services. Full disclaimer: http://dreamteamgroup.com/disclaimer.html
stockseeker30
 
Posts: 0
Joined: Sat Aug 21, 2010 9:02 pm

Re: Boston Therapeutics, Inc. (BTHE)

Postby QualityStocks » Tue Oct 15, 2013 8:19 pm

Boston Therapeutics, Inc. (BTHE) Begins Research Study on PAZ320 at University of Minnesota

Boston Therapeutics today announces it has initiated a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. Entitled “NMR studies of PAZ320 with sugar hydrolyzing enzymes”, the study will be conducted by Kevin H. Mayo, Ph.D., a professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota, Minneapolis.

Dr. Mayo commented, “PAZ320 appears to be a promising compound in the treatment of diabetes and deserves closer evaluation by the scientific community. This Boston Therapeutics-supported investigation is designed to assess biomolecular interactions between PAZ320 and various sugar hydrolyzing enzymes, and should contribute to understanding PAZ320′s mechanism of action on the molecular level.”

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, “We are greatly encouraged by the results obtained to date regarding the ability of PAZ320 to reduce the elevation of post-meal blood glucose. We expect this new study at the University of Minnesota will deepen our understanding of this compound on a molecular level, and strengthen our knowledge of its potential as a drug for diabetes patients.”

The study’s purpose is to provide molecular-level information on PAZ320 and its mechanism of action. More particularly, the study is intended to better characterize PAZ320 galactomannan, and assess interactions of PAZ320 with various sugar-hydrolyzing enzymes (e.g., glucosidase and maltase). Furthermore, it may produce insights into the allosteric properties of PAZ320 with enzymes, gauge the effect of PAZ320 on enzyme-mediated sugar hydrolysis, and compare PAZ320 with other diabetes drugs.

Boston Therapeutics is a developer of drugs based on complex carbohydrate chemistry to treat diabetes. It is primarily focused currently on developing and commercializing therapeutic molecules for Type 2 diabetes, of which PAZ320 is one.

For additional information, visit www.BostonTI.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 433
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Boston Therapeutics, Inc. (BTHE)

Postby protostars » Wed Oct 16, 2013 5:23 am

An important early study on what could become a blockbuster drug, targeting diabetes sufferers all over the world.
Please see profile for disclaimer
protostars
 
Posts: 0
Joined: Mon Jan 19, 2009 11:20 am
Location: Arizona

Next

Return to QualityStocks Previous Clients

Who is online

Users browsing this forum: No registered users and 2 guests

cron